Catherine Fagard

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial

Yazdan Yazdanpanah, Catherine Fagard, Diane Descamps et al. · Clinical Infectious Diseases · 2009 · 237 citations

Medicine, Pharmacology, Pharmacotherapy +17

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

Annette Oxenius, David A. Price, Huldrych F. Günthard et al. · Proceedings of the National Academy of Sciences · 2002 · 214 citations

Life Sciences, Immunology, Infectious Diseases +15

A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection

Catherine Fagard · Archives of Internal Medicine · 2003 · 177 citations · Full text

Public Health, Immunology, Infectious Diseases +14

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

Beatriz Grinsztejn, Nathalie De Castro, Vincent Arnold et al. · The Lancet Infectious Diseases · 2014 · 98 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

Sabine Yerly, Huldrych F. Günthard, Catherine Fagard et al. · AIDS · 2004 · 76 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +17